ely to change and speak only as of the
date hereof.
(Tables Follow)
TorreyPines Therapeutics, Inc.
Condensed Consolidated Balance Sheets
(in thousands)
September 30, December 31,
2007 2006
(Unaudited)
Assets
Current assets
Cash and cash equivalents $39,723 $55,383
Prepaid expenses and other current assets 289 581
Total current assets 40,012 55,964
Long-term assets 7,025 7,471
Total assets $47,037 $63,435
Liabilities and stockholders' equity
Current liabilities $8,745 $12,270
Debt and other long-term liabilities 1,871 4,413
Deferred revenue 2,083 2,183
Total liabilities 12,699 18,866
Total stockholders' equity 34,338 44,569
Total liabilities and stockholders' equity $47,037 $63,435
TorreyPines Therapeutics, Inc.
Condensed Consolidated Statements of Operations
(in thousands, except per share amounts)
(Unaudited)
Three months ended Nine months ended
September 30, September 30,
2007 2006 2007 2006
Revenue $2,463 $2,463 $7,388 $7,388
Operating expenses:
Resea
'/>"/>
SOURCE TorreyPines Therapeutics, Inc. Copyright©2007 PR Newswire. All rights reserved | |
Page: 1 2 3 4 5 6 Related biology technology :1.
TorreyPines Therapeutics to Present at the NewsMakers in the Biotech Industry Conference2.
TorreyPines Therapeutics to Present at ThinkEquitys G5 Conference3.
TorreyPines Therapeutics and Eisai Co., Ltd. Extend Genetics Discovery Collaboration for Alzheimers Disease4.
TorreyPines Therapeutics to Present at ThinkEquitys ThinkClinic Conference5.
TorreyPines Therapeutics to Present at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference6.
Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA7.
DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review8.
PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation9.
Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway10.
Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 200711.
Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer